SCHEMBL18345083

SCHEMBL18345083

Oc1cc2cn[nH]c2cc1F

nearest known ligand 0.60

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
FGFR1 P11362 4/20 0.60
FGFR2 P21802 3/20 0.60
CHEK1 O14757 1/20 0.48
TRPA1 O75762 2/20 0.46
FGFR3 P22607 1/20 0.44
TNIK Q9UKE5 1/20 0.43
MKNK1 Q9BUB5 1/20 0.43
INSR P06213 1/20 0.42
IGF1R P08069 1/20 0.42
METAP2 P50579 3/20 0.42
NOS1 P29475 5/20 0.41
KDM4E B2RXH2 2/20 0.41
MEN1 O00255 2/20 0.41
MAPT P10636 2/20 0.41
KMT2A Q03164 2/20 0.41
DYRK1A Q13627 2/20 0.41
PKM P14618 1/20 0.41
HTT P42858 1/20 0.41
CSNK2A1 P68400 1/20 0.41
ROCK2 O75116 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL31633137 1.00 FGFR1 (0.60) FGFR1FGFR2CHEK1TRPA1FGFR3
SCHEMBL30536603 0.92 FGFR1 (0.60) FGFR1FGFR2CHEK1TRPA1FGFR3
SCHEMBL14738406 0.83 CHEK1 (0.56) FGFR1FGFR2CHEK1TRPA1MKNK1
SCHEMBL28263674 0.83 CHEK1 (0.56) FGFR1FGFR2CHEK1FGFR3INSR
SCHEMBL13692758 0.78 NOS1 (0.52) FGFR1FGFR2CHEK1TRPA1MKNK1
SCHEMBL1360997 0.78 FGFR1 (0.62) FGFR1FGFR2CHEK1TRPA1FGFR3
SCHEMBL23977642 0.76 NOS1 (0.50) FGFR1FGFR2CHEK1TRPA1METAP2
SCHEMBL828690 0.76 AXL (0.56) FGFR1FGFR2CHEK1TRPA1MKNK1
SCHEMBL12435218 0.76 CHEK1 (0.48) FGFR1FGFR2CHEK1TRPA1METAP2
SCHEMBL1273798 0.76 CHEK1 (0.70) FGFR1FGFR2CHEK1TRPA1MKNK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250368666-A1 INDAZOLE COMPOUNDS TYRA BIOSCIENCES INC (US) 2025-12-04 US disclosed
US-20250340533-A1 INDAZOLE COMPOUNDS AS KINASE INHIBITORS TYRA BIOSCIENCES INC (US) 2025-11-06 US disclosed
WO-2025129167-A1 INHIBITORS OF THE SURFACE EXPRESSION OF THE VOLTAGE-GATED SODIUM ION CHANNEL 1.7 (NAV1.7) AND THEIR THERAPEUTIC USES THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPT. OF HEALTH AND HUMAN SERVICES (US) 2025-06-19 WO disclosed
EP-4547656-A1 INDAZOLE COMPOUNDS Tyra Biosciences, Inc. (US) 2025-05-07 EP disclosed
US-12264149-B2 Indazole compounds as kinase inhibitors TYRA BIOSCIENCES, INC. (US) 2025-04-01 US disclosed
CN-119731165-A Indazole compounds 泰拉生物科学公司 2025-03-28 CN disclosed
US-12071428-B2 Indazole compounds as kinase inhibitors TYRA BIOSCIENCES, INC. (US) 2024-08-27 US disclosed
US-20240208941-A1 INDAZOLE COMPOUNDS AS KINASE INHIBITORS TYRA BIOSCIENCES, INC. 2024-06-27 US disclosed
US-20240208941-A1 INDAZOLE COMPOUNDS AS KINASE INHIBITORS TYRA BIOSCIENCES, INC. 2024-06-27 US disclosed
US-20240109865-A1 INDAZOLE COMPOUNDS AS KINASE INHIBITORS TYRA BIOSCIENCES, INC. 2024-04-04 US disclosed
EP-3313396-B1 G PROTEIN-COUPLED RECEPTOR KINASE INHIBITORS AND METHODS FOR USE OF THE SAME UNIV MICHIGAN REGENTS (US) 2021-12-15 EP disclosed
EP-3313396-B1 G PROTEIN-COUPLED RECEPTOR KINASE INHIBITORS AND METHODS FOR USE OF THE SAME UNIV MICHIGAN REGENTS (US) 2021-12-15 EP disclosed
WO-2021219090-A1 QUINOXALINE DIONE DERIVATIVE AS IRREVERSIBLE INHIBITOR OF KRAS G12C MUTANT PROTEIN 北京泰德制药股份有限公司 (CN) 2021-11-04 WO disclosed
US-10329283-B2 G protein-coupled receptor kinase inhibitors and methods for use of the same THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) 2019-06-25 US disclosed
US-10329283-B2 G protein-coupled receptor kinase inhibitors and methods for use of the same THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) 2019-06-25 US disclosed
US-20180186779-A1 G PROTEIN-COUPLED RECEPTOR KINASE INHIBITORS AND METHODS FOR USE OF THE SAME THE REGENTS OF THE UNIVERSITY OF MICHIGAN 2018-07-05 US disclosed
US-20180186779-A1 G PROTEIN-COUPLED RECEPTOR KINASE INHIBITORS AND METHODS FOR USE OF THE SAME THE REGENTS OF THE UNIVERSITY OF MICHIGAN 2018-07-05 US disclosed
US-20180186779-A1 G PROTEIN-COUPLED RECEPTOR KINASE INHIBITORS AND METHODS FOR USE OF THE SAME THE REGENTS OF THE UNIVERSITY OF MICHIGAN 2018-07-05 US disclosed
EP-3313396-A1 G PROTEIN-COUPLED RECEPTOR KINASE INHIBITORS AND METHODS FOR USE OF THE SAME The Regents of The University of Michigan (US) 2018-05-02 EP disclosed
WO-2016210403-A1 G PROTEIN-COUPLED RECEPTOR KINASE INHIBITORS AND METHODS FOR USE OF THE SAME THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) 2016-12-29 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12071428-B2 Indazole compounds as kinase inhibitors FGFR1, FGFR2, FGFR3 FGFR1 1/4885FGFR2 2/4885CHEK1 131/4885
US-20240208941-A1 INDAZOLE COMPOUNDS AS KINASE INHIBITORS FGFR1, FGFR2, FGFR3 FGFR1 1/4885FGFR2 2/4885CHEK1 131/4885
US-10329283-B2 G protein-coupled receptor kinase inhibitors and methods for use of the same GRK2, GRK4, GRK3 FGFR1 403/4885FGFR2 776/4885CHEK1 1971/4885
US-20180186779-A1 G PROTEIN-COUPLED RECEPTOR KINASE INHIBITORS AND METHODS FOR USE OF THE SAME GRK2, GRK4, GRK3 FGFR1 403/4885FGFR2 776/4885CHEK1 1971/4885
US-20250340533-A1 INDAZOLE COMPOUNDS AS KINASE INHIBITORS FGFR1, FGFR2, FGFR3 FGFR1 1/4885FGFR2 2/4885CHEK1 131/4885
US-20250368666-A1 INDAZOLE COMPOUNDS FGFR1, FGFR3, FGFR2 FGFR1 1/4885FGFR2 3/4885CHEK1 576/4885
US-12264149-B2 Indazole compounds as kinase inhibitors FGFR1, FGFR2, FGFR3 FGFR1 1/4885FGFR2 2/4885CHEK1 131/4885
US-20240109865-A1 INDAZOLE COMPOUNDS AS KINASE INHIBITORS FGFR1, FGFR2, FGFR3 FGFR1 1/4885FGFR2 2/4885CHEK1 131/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.